Current Evidence on Therapeutic Approaches to BCBM: HER2-Negative Disease

Expert review and discussion of key data from SABCS 2020 in HER2-positive and hormone receptor–positive/HER2-negative disease, and metastatic triple-negative breast cancer from Clinical Care Options (CCO)

Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: February 19, 2021 Expired: February 18, 2022

Download this short summary slideset oncurrent treatment for patients with HER2-positive breast cancer, from NCCN and Clinical Care Options (CCO).

Jame Abraham, MD, FACP Hope S. Rugo, MD Sara Tolaney, MD, MPH Released: February 9, 2021

Download these expert-selected slides on treating patients with HER2-positive metastatic breast cancer, from NCCN and Clinical Care Options (CCO).

Hope S. Rugo, MD Released: February 3, 2021

Download these expert-selected slides on treatment for patients with HER2-positive early breast cancer, from NCCN and Clinical Care Options (CCO).

Jame Abraham, MD, FACP Released: February 2, 2021